Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Pritalix BioTherapeutics Issues A Letter To Shareholders Reflecting On Transformation On Its Accomplishments In 2020 A Submission To The FDA For Its Biologics License Application For PRX-102 Dor The Treatment Of Adults With Fabry Disease


Benzinga | Dec 30, 2020 06:57AM EST

Pritalix BioTherapeutics Issues A Letter To Shareholders Reflecting On Transformation On Its Accomplishments In 2020 A Submission To The FDA For Its Biologics License Application For PRX-102 Dor The Treatment Of Adults With Fabry Disease






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC